SGPL1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL229161	0.37	13/20
SCHEMBL227694	0.35	10/20
SCHEMBL2292830	0.61	7/20
SCHEMBL2224631	0.51	7/20
SCHEMBL1811690	0.47	6/20
SCHEMBL1814909	0.62	5/20
SCHEMBL229219	0.33	5/20
SCHEMBL3885	0.65	4/20
SCHEMBL3886	0.65	4/20
SCHEMBL861987	0.63	4/20
SCHEMBL1273298	0.63	4/20
SCHEMBL43371	0.61	4/20
SCHEMBL195872	0.61	4/20
SCHEMBL1206743	0.58	4/20
SCHEMBL865554	0.56	4/20
SCHEMBL1055043	0.55	4/20
Sphingosine (SCHEMBL1161567)	0.54	4/20
SCHEMBL28646	0.54	4/20
SCHEMBL2150095	0.54	4/20
SCHEMBL2398671	0.53	4/20

Clinical trials — most relevant to SGPL1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Sphingosine-1-phosphate and Pneumonia	PHASE2/PHASE3	UNKNOWN
Hereditary Sensory Neuropathy Serine Trial	PHASE2	UNKNOWN
Repurposing Siponimod for Alzheimer's Disease	PHASE2	RECRUITING
Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo	PHASE2	COMPLETED
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.	PHASE1	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)	nan	RECRUITING
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma	nan	RECRUITING
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure	nan	COMPLETED
Sphingo-lipotoxicity and Trans-differentiation of Adipose Tissue in Obesity (SFINGOTRANS)	nan	COMPLETED
Studying Lipids as Potential Biomarkers in Patients With Fabry Disease	nan	COMPLETED
Identification of Biomarkers and Molecular Targets Involved on Intervertebral Disc Degeneration and Discogenic Pain	nan	UNKNOWN
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma	nan	SUSPENDED
Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod	nan	COMPLETED
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study	nan	UNKNOWN
SPL Insufficiency Syndrome (SPLIS)/NPHS14: a SPLIS Observational Study and Patient Registry (International)	nan	RECRUITING
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes	nan	COMPLETED
Development of Therapeutic Approaches Modulating Molecular Targets Implicated on Cancer Stem Cell-related Aggressiveness	nan	UNKNOWN
Study of the Prevalence of Acid Sphingomyelinase Deficiency/Niemann Pick AB and B Disease in Patients With Diffuse Interstitial Lung Disease	nan	NOT_YET_RECRUITING
Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis	nan	UNKNOWN
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children	nan	NOT_YET_RECRUITING
A Long-Term Study of Cholesterol Supplements for Smith-Lemli-Opitz Syndrome	nan	WITHDRAWN
Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)	nan	UNKNOWN
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales	nan	RECRUITING
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
Biomarker for Farber Disease (BioFarber)	nan	WITHDRAWN
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease	nan	WITHDRAWN
Ceramide Level as Apredictor of Outcomes in Patients of Anterior Myocardial Infarction Undergoing Primary Coronary Intervention	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SGPL1 binder may also engage these)

Protein	Name	Similarity
Q8R0X7	—	1.000	Q8R0X7 →
Q5R4G0	—	1.000	Q5R4G0 →
Q8CHN6	—	1.000	Q8CHN6 →
Q9V7Y2	—	0.993	Q9V7Y2 →
Q52RG7	—	0.991	Q52RG7 →
Q9C509	—	0.988	Q9C509 →
Q05567	—	0.985	Q05567 →
Q06086	—	0.985	Q06086 →
Q8RYL1	—	0.983	Q8RYL1 →
Q54RV9	—	0.983	Q54RV9 →
Q28F67	—	0.983	Q28F67 →
Q8RY79	—	0.983	Q8RY79 →
A0A2H5AIY2	—	0.983	A0A2H5AIY2 →
Q9Y194	—	0.982	Q9Y194 →
DDC	Aromatic-L-amino-acid decarboxylase	0.982	landscape →
Q5REB0	—	0.982	Q5REB0 →
SPTLC3	Serine palmitoyltransferase 3	0.982	landscape →
Q3B7D2	—	0.981	Q3B7D2 →
GOT2	Aspartate aminotransferase, mitochondrial	0.981	landscape →
Q7XHL3	—	0.981	Q7XHL3 →
Q54VQ5	—	0.981	Q54VQ5 →
Q9M304	—	0.981	Q9M304 →
P17770	—	0.981	P17770 →
Q5JK39	—	0.981	Q5JK39 →
P00508	—	0.980	P00508 →
A0A2H5AIY0	—	0.980	A0A2H5AIY0 →
O96567	—	0.980	O96567 →
O88533	—	0.979	O88533 →
P05031	—	0.979	P05031 →
P00507	—	0.979	P00507 →